IP Library Granted Patent US 7,063,864
Granted Patent B1
US 7,063,864 · App. 10/009,341 · Granted Jun 20, 2006

Morphine sulphate microgranules, method for preparing same and compositions containing same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,063,864
App. No.
10/009,341
Granted
Jun 20, 2006
Kind
B1
Abstract

The present invention concerns a novel sustained-release oral formulation of morphine sulphate in the form of microgranules. Each microgranule comprises a neutral support grain coated with an active layer and with a sustained-release layer, characterized in that the sustained-release layer contains a copolymer of methacrylic acid and of methyl methacrylate ester, the relative proportion of the free carboxyl groups and of the ester groups of which is equal to 0.5 approximately, and a silica exhibiting a hydrophobic character. The present invention also concerns a process for preparing these microgranules which is carried out entirely in aqueous medium by emplacing on neutral support grains.

Claims (82)

1. Sustained-release morphine sulphate microgranules each comprising a neutral support grain coated with an active layer and with a sustained-release layer, said sustained-release layer containing:

a copolymer of poly(ethylacrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) 1:2:0.1;

a plasticizer; and

a lubricant;

wherein said sustained-release layer further comprises a hydrophobic silica which represents 0.2 to 1% by weight of the microgranules and wherein said microgranules are devoid of any outer protective film.

2. Microgranules according to claim 1 , characterized in that the relative mass proportion of the morphine sulphate and of the neutral support grain is between 40/60 and 60/40.

3. Microgranules according to claim 1 , characterized in that the morphine sulphate represents 30 to 40% by mass of the microgranules.

4. Process for preparing the microgranules according to claim 1 , characterized in that the active layer and the sustained-release layer are applied onto the neutral grains by emplacing in aqueous solution.

5. Pharmaceutical composition containing the microgranules according to claim 1 , optionally obtained according to the process for preparing the microgranules, characterized in that the active layer and the sustained-release layer are applied onto the neutral grains by emplacing in aqueous solution.

6. Microgranules according to claim 1 , wherein the plasticizer is triethylcitrate.

7. Microgranules according to claim 1 , further comprising 30–40% wt neutral support grain.

8. Microgranules according to claim 1 , further comprising 10–20% wt binder.

9. Microgranules according to claim 1 , further comprising 1–2.5% wt plasticizer.

10. Microgranules according to claim 1 , further comprising 2–4% wt lubricant.

11. Microgranules according to claim 1 , further comprising 5–15% wt methacrylic acid copolymer.

12. Microgranules according to claim 1 , further comprising 30–40% wt morphine sulphate, 30–40% wt neutral support grain, 10–20% wt binder, 1–2.5% wt plasticizer, 2–4% wt lubricant, and 0.2–1% wt hydrophobic silica.

13. Microgranules according to claim 1 , characterized in that they have the following composition (% by mass):

morphine sulphate

37.3

neutral grains

37.3

hydroxypropylmethylcellulose

13.0

poly(ethylacrylate, methyl methacrylate,

8.2

trimethylammonioethyl methacrylate chloride) 1:2:0.1

triethylcitrate

1.6

talc and

2.1

hydrophobic silica

0.4.

14. Microgranules according to claim 1 , characterized in that they have the following composition (% by mass):

morphine sulphate

35.1

neutral grains

39.7

Hydroxypropylmethylcellulose

12.3

poly(ethylacrylate, methyl methacrylate,

8.2

trimethylammonioethyl methacrylate chloride) 1:2:0.1

Triethylcitrate

1.6

talc and

2.6

hydrophobic silica

0.4.

15. Microgranules according to claim 1 , characterized in that they have the following composition (% by mass):

morphine sulphate

40.9

neutral grains

34.3

hydroxypropylmethylcellulose

14.3

poly(ethylacrylate, methyl methacrylate,

6.7

trimethylammonioethyl methacrylate chloride) 1:2:0.1

triethylcitrate

1.3

talc and

2.2

hydrophobic silica

0.3.

16. Microgranules according to claim 1 , characterized in that they have the following composition (% by mass):

morphine sulphate

41.9

neutral grains

33.0

Hydroxypropylmethylcellulose

11.7

PEG 4000

2.9

poly(ethylacrylate, methyl methacrylate,

7.3

trimethylammonioethyl methacrylate chloride) 1:2:0.1

Triethylcitrate

1.4

Talc

1.4

hydrophobic silica

0.4.

Assignments (2)
CHANGE OF NAME Recorded Jan 16, 2007
From: LABORATOIRES DES PRODUITS ETHIQUES ETHYPHARM
To: ETHYPHARM
Reel/Frame 018761/0135 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2002
From: MARECHAL, DOMINIQUE; SUPLIE, PASCAL; OURY, PASCAL
To: LABORATOIRES DES PRODUCTS ETHIQUES ETHYPHARM
Reel/Frame 013189/0238 →